In the midst of a worsening crisis over opioid use and prescribing, you might think a company would take every precaution to ensure its medicine is marketed carefully to physicians.
But one small drug maker failed to do so — in a big way.
In promotional materials that were distributed to doctors, Vertical Pharmaceuticals omitted some rather important risk information about ConZip, an opioid painkiller, according to a warning letter the Food and Drug Administration issued late last month and posted on its web site earlier this month.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect